- PROCESS FOR THE PREPARATION OF 4-(4-AMINOPHENYL)MORPHOLIN-3-ONE
-
The field of this invention relates to a novel process, suitable for industrial scale manufacture, for the preparation of 4-(4-aminophenyl)morpholin-3-one of Formula (I), the key intermediate of rivaroxaban according to the scheme. In the process 2-(2-chloroethoxy)ethanol of Formula (XI) is oxidized to 2-(2-chloroethoxy)- acetic acid with aqueous sodium- or calcium-hypochlorite and a catalyst. The 2-(2~ chloroethoxy)acetic acid of Formula (X) is reacted with 4-nitro-aniline of Formula (VII) with phenylboronic acid catalyst. Then the 2-(2-chloroetoxy)-N-(4-nitrophenyl)acetamide of Formula (IX) is transformed to 4-(4-nitrophenyl)morpholin-3-one of Formula (IV) in a ?one- pot" procedure. The 4-(4-nitrophenyl)morpholin-3-one of Formula (IV) is hydrogenated to get 4-(4-aminophenyl)morpholin-3-one of Formula (I).
- -
-
Page/Page column 10
(2019/08/20)
-
- A the advantage cuts down Sha Ban preparation method of the midbody and intermediate
-
The invention discloses a preparation method of a rivaroxaban intermediate and an intermediate. The invention discloses a preparation method of a compound represented by the formula 4. The preparation method comprises a step of making a compound 3 carry out a ring closing reaction, which is represented in the description, so as to obtain the compound 4. The invention also discloses a preparation method of a compound represented by the formula 3 and a preparation method of a compound represented by the formula 1. The invention also discloses a compound represented by the formula 3 and a compound represented by the formula 5. The preparation method has the advantages of easily-available and cheap raw materials, simple technology and post-treatment, easy purification of intermediate and end products, high total yield, and high purity, and is easy for being applied to industrial production.
- -
-
Paragraph 0238; 0240; 0241
(2017/08/25)
-
- METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES
-
The invention relates to a method for production of compounds of formula (I), where X has the meaning given in claim 1 and precursors for the same.
- -
-
Page/Page column 23; 24
(2008/06/13)
-
- Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa
-
Neutral chlorothiophenecarboxamides bearing an amino acid and a substituted aniline were synthesized and investigated for their factor Xa inhibitory activity in vitro. From selected 2-methylphenyl morpholinones the solution properties were determined. The most soluble and active compounds were then investigated in different animal species to compare the pharmacokinetic parameters. This led to a potent, water soluble and orally bioavailable candidate for further development: EMD 495235.
- Mederski, Werner W.K.R.,Cezanne, Bertram,Amsterdam, Christoph Van,Bühring, Karl-Ulrich,Dorsch, Dieter,Gleitz, Johannes,M?rz, Joachim,Tsaklakidis, Christos
-
p. 5817 - 5822
(2007/10/03)
-